On the other hand, since (1) there are conflicting data on EGFR expression in UCC and normal bladder mucosa and (2) EGFR expression in normal bladder cells may possibly increase side effect of EIMPDNE-mediated treatment, the PFC double emulsion-based drug carrier can be decorated by other cell surface proteins that are overexpressed or aberrantly expressed in bladder cancer cells, such as FGFR-3, ErbB-2, Nectin-4, Muc-1, CEA, and so forth, in order to improve the availability or clinical utility of the nanodroplet. The gene discussed is NECTIN4; the disease is urinary bladder cancer.